SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the pending FDA decision for Capricors Duchenne muscular dystrophy treatment deramiocel, with a letter from 28 HOPE-3 investigators urging approval and disputing the agencys interpretation of the trial data. Many traders are optimistic and discuss call activity and short-squeeze potential, while others stress that approval is uncertain and a rejection or delay remains possible.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon shares are selling off after quarterly results missed expectations and management lowered its full-year revenue outlook, citing federal procurement delays. Traders are focused on the cautious outlook and rich valuation, while some argue the companys ongoing growth and public-safety technology demand make the pullback a buying opportunity.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias steep drop is part of a broader semiconductor selloff as traders weigh whether post-election calls for tighter data-center controls could slow AI infrastructure spending. The community is split between fears of a lasting AI-capex reset and dip buyers who argue the concerns are overblown and projects can shift elsewhere.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

A sharp selloff in semiconductor and AI-linked stocks has drawn attention to SOXS, as traders debate concerns about AI and data-center spending, sector valuations, and election-related policy uncertainty. Some expect more downside in chips, while others warn of a sharp rebound and note that SOXSs leverage and daily resets make it a volatile short-term trade.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs quarterly results showed rapid growth in its AI cloud business and a large contracted backlog, but the rollout of its more than $4 billion annualized-revenue target was pushed to January or February after a customer design change. Traders are split between viewing the results and customer prepayments as a basis for a rebound and focusing on execution delays, heavy capital needs and debt amid a broader selloff in AI-infrastructure stocks.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios Q3 results beat expectations and its full-year outlook improved, but weaker Q4 organic-growth guidance signaled a slowdown from the prior quarter and triggered a sharp selloff. Traders are debating whether the decline is an overreaction to the guidance or a justified reset for slowing growth, while some watch for a rebound.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a sharp semiconductor selloff as traders worry that post-election scrutiny of data-center construction could slow AI infrastructure spending and chip demand. The community is split between viewing the drop as an overreaction and buying opportunity, and expecting further downside amid AI-bubble and memory-cycle concerns.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A broad market selloff, led by tech and semiconductor weakness, has weighed on the Dow as traders debate whether political pushback could slow AI and data-center investment. The community is largely bearish after the sharp decline, though some see the Dows relative resilience and rotation away from tech as a buying opportunity.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Unusual options activity is drawing attention to Barrick, with traders discussing early call-heavy flow but also later put-heavy positioning as the shares weaken. The community is split between concern that a technical correction in gold miners could deepen and longer-term optimism about gold, copper and mining fundamentals.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have filed an FDA application for psilocybin in major depression has fueled a sharp selloff and raised concerns about competition and which company could reach market first; the filing has not been publicly confirmed. Traders debate whether the threat is overstated because Compass is developing COMP360 for treatment-resistant depression and has commercial infrastructure, while watching for completion of its own NDA submission.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD

MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWDPR NewswireNEW YORK, Oct. 25, 2026 NEW YORK, Oct. 25, 2026 /PRNewswire/ -- Class Action...

EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger -- UTZ, SAFT, PASG and FNWD - IS IT A FAIR DEAL FOR YOU?

EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger -- UTZ, SAFT, PASG and FNWD - IS IT A FAIR DEAL FOR YOU? EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger -- UTZ, SAFT, PASG and FNWD - IS IT A FAIR DEAL FOR YOU?PR NewswireNEW YORK, Oct. 21, 2026 NEW YORK, Oct...

PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the proposed transaction, Passage Bio shareholders are expected to own approximately 7% of the combined company. Halper Sadeh encourages...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026 /PRNewswire...

SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today

Equity

The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans. 


PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Passage Bio said on Wednesday that it will merge with privately held Remix Therapeutics. 


Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?

Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside...

This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Passage Bio. See analyst ratings for these stocks.read more...

Passage Bio (NASDAQ:PASG) CEO Sells $75,161.44 in Stock

Passage Bio, Inc. (NASDAQ:PASG - Get Free Report) CEO William Chou sold 4,076 shares of the business's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of...

Insider Selling: Passage Bio (NASDAQ:PASG) CEO Sells $75,161.44 in Stock

Passage Bio, Inc. (NASDAQ:PASG - Get Free Report) CEO William Chou sold 4,076 shares of the firm's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of...

Passage Bio, Inc. operates as a genetic medicines company. It focuses on development of therapies for central nervous system disorders. The company was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Passage Bio Inc

Neutral Sentiment

<ul class="summary-bullets"><li>ARS Pharmaceuticals shares tumbled after the company said Neffy failed to secure expanded commercial insurance coverage for the July 1 review cycle.&nbsp;</li><li>Passage Bio shares fell after the company agreed to merge with Remix Therapeutics in an all-stock deal.</li><li>Boxlight shares dropped after hours following a speculative rally fueled by the company's recent 1-for-6 reverse stock split.&nbsp;</li></ul>ARS Pharmaceuticals (SPRY), Passage Bio (PASG), and Boxlight Corp. (BOXL),&nbsp;all small-cap stocks, posted double-digit losses in after-hours trading on Wednesday as investors digested new business developments.<h2 class="st-heading-2">SPRY Faces Coverage Setback</h2>ARS Pharmaceuticals shares came under heavy selling after investors reacted to an <a href="https://stocktwits.com/news-articles/markets/equity/spry-stock-tanks-after-hours-ars-pharmaceuticals-reports-no-new-major-insurance-wins-for-neffy/cZK6ySGR7Q4">update</a> on insurance coverage for Neffy, the company's needle-free treatment for severe allergic reactions.&nbsp;The stock fell after the company said talks with health insurers did not lead to broader coverage for the July 1 review cycle. Investors saw the setback as a challenge to sales growth and increased product use.&nbsp;Commercial insurance support often plays a major role in determining how quickly newly approved therapies gain traction. Additionally, the company lowered its projected 2026 cash-based operating expense forecast to approximately $248 million.&nbsp;<a href="https://stocktwits.com/symbol/SPRY">ARS Pharmaceuticals’ stock</a> traded over 24% lower overnight. On Stocktwits, retail sentiment around the stock&nbsp;improved to ‘neutral’ from ‘bearish’ the previous day.&nbsp;<h2 class="st-heading-2">PASG Drops Following Deal Announcement</h2>Passage Bio declined after unveiling a <a href="https://stocktwits.com/news-articles/markets/equity/pasg-stock-slumps-after-hours-whats-driving-the-selloff/cZKyoZ4R7Q5">merger</a> agreement involving Remix Therapeutics, Inc. The companies have agreed to combine through an all-stock transaction that will create a publicly traded biotechnology company focused on RNA-processing therapies.&nbsp;The merged business plans to operate as Remix Therapeutics and list its shares on Nasdaq under the ticker symbol RMTX following the completion of the deal with existing Passage Bio shareholders expected to own roughly 7% of the combined entity.&nbsp;The transaction is accompanied by an oversubscribed private financing expected to generate approximately $100 million in gross proceeds from a group of investors led by Decheng Capital.<a href="https://stocktwits.com/symbol/PASG">Passage Bio stock</a> traded over 15% lower overnight. Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">Post-Split Volatility Drives Sharp Reversal In BOXL After Massive Rally&nbsp;</h2>Boxlight shares pulled back in after-hours trading after jumping 37% during the regular session. The education technology company, which recently&nbsp;completed a reverse stock split to remain listed on Nasdaq, saw investors take profits after a surge driven by heavy speculative buying.&nbsp;The decline followed a daytime surge that pushed shares significantly higher before momentum faded. Traders appeared to reassess positions after a rapid advance fueled by heavy volume and a reduced share count.On Monday, Boxlight implemented a 1-for-6 reverse stock split, which reduced the number of authorized Class A shares, creating a much tighter trading float and increasing the stock’s sensitivity to buying and selling activity.<a href="https://stocktwits.com/symbol/BOXL">Boxlight stock</a> traded over 17% lower overnight. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day.&nbsp;So far this year, PASG and BOXL stocks have plunged 50% and 52%, respectively, while SPRY stock has declined 9%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfe-stock-continues-to-drop-as-lung-cancer-trial-disappointment-overshadows-ibrance-win/cZKyn58R7Qc">PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

ARS Pharmaceuticals (SPRY), Passage Bio (PASG), and Boxlight Corp. (BOXL),&nbsp;all small-cap stocks, posted double-digit losses in after-hours trading on Wednesday as investors digested new business developments.

Boxlight Corp

ARS Pharmaceuticals Inc

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$3.46
Prev Close	$3.51
Open	$3.52
Dividend Yield	0.00%
50-Day Moving Average	$4.18
Beta	1.83
Avg. Volume	16,530.83
PE Ratio	-0.31

52-Week High	$20.00
52-Week Low	$3.29
Market Capitalization	$11.29M
EPS (Annual)	-$14.35
Price to Book	2.50
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PASG Fundamentals